- Application under evaluation
- CVMP opinion
- European Commission decision
Overview
The marketing authorisation for Bovalto Ibraxion has been withdrawn at the request of the marketing authorisation holder.
Bovalto Ibraxion : EPAR - Summary for the public
English (EN) (211.7 KB - PDF)
български (BG) (273.86 KB - PDF)
español (ES) (211.53 KB - PDF)
čeština (CS) (261.66 KB - PDF)
dansk (DA) (213.32 KB - PDF)
Deutsch (DE) (220.08 KB - PDF)
eesti keel (ET) (204.87 KB - PDF)
ελληνικά (EL) (286.33 KB - PDF)
français (FR) (212.65 KB - PDF)
hrvatski (HR) (231.45 KB - PDF)
italiano (IT) (209.38 KB - PDF)
latviešu valoda (LV) (244.51 KB - PDF)
lietuvių kalba (LT) (233 KB - PDF)
magyar (HU) (249.94 KB - PDF)
Malti (MT) (258.21 KB - PDF)
Nederlands (NL) (211.02 KB - PDF)
polski (PL) (256.51 KB - PDF)
português (PT) (211.11 KB - PDF)
română (RO) (235.21 KB - PDF)
slovenčina (SK) (258.12 KB - PDF)
slovenščina (SL) (244.33 KB - PDF)
Suomi (FI) (209.31 KB - PDF)
svenska (SV) (209.74 KB - PDF)
Product information
Bovalto Ibraxion : EPAR - Product Information
English (EN) (673.53 KB - PDF)
български (BG) (705.71 KB - PDF)
español (ES) (674.36 KB - PDF)
čeština (CS) (969.79 KB - PDF)
dansk (DA) (624.29 KB - PDF)
Deutsch (DE) (661.81 KB - PDF)
eesti keel (ET) (692.55 KB - PDF)
ελληνικά (EL) (1.19 MB - PDF)
français (FR) (671.79 KB - PDF)
hrvatski (HR) (767.57 KB - PDF)
íslenska (IS) (680.52 KB - PDF)
italiano (IT) (679.81 KB - PDF)
latviešu valoda (LV) (999.57 KB - PDF)
lietuvių kalba (LT) (791.74 KB - PDF)
magyar (HU) (981.94 KB - PDF)
Malti (MT) (1007.77 KB - PDF)
Nederlands (NL) (671.31 KB - PDF)
norsk (NO) (684.14 KB - PDF)
polski (PL) (993.05 KB - PDF)
português (PT) (664.06 KB - PDF)
română (RO) (792.26 KB - PDF)
slovenčina (SK) (995.67 KB - PDF)
slovenščina (SL) (960.57 KB - PDF)
Suomi (FI) (678.92 KB - PDF)
svenska (SV) (676.34 KB - PDF)
Bovalto Ibraxion : EPAR - All Authorised presentations
English (EN) (172.18 KB - PDF)
български (BG) (333.69 KB - PDF)
español (ES) (172.7 KB - PDF)
čeština (CS) (205.62 KB - PDF)
dansk (DA) (172.68 KB - PDF)
Deutsch (DE) (173.21 KB - PDF)
eesti keel (ET) (168.31 KB - PDF)
ελληνικά (EL) (215.76 KB - PDF)
français (FR) (171.23 KB - PDF)
hrvatski (HR) (192.67 KB - PDF)
íslenska (IS) (170.24 KB - PDF)
italiano (IT) (168.65 KB - PDF)
latviešu valoda (LV) (209.34 KB - PDF)
lietuvių kalba (LT) (200.78 KB - PDF)
magyar (HU) (191.94 KB - PDF)
Malti (MT) (214.75 KB - PDF)
Nederlands (NL) (170.59 KB - PDF)
norsk (NO) (168.61 KB - PDF)
polski (PL) (207.14 KB - PDF)
português (PT) (172.47 KB - PDF)
română (RO) (195.44 KB - PDF)
slovenčina (SK) (209.19 KB - PDF)
slovenščina (SL) (240.02 KB - PDF)
Suomi (FI) (166.83 KB - PDF)
svenska (SV) (172.67 KB - PDF)
Product details
- Name of medicine
- Bovalto Ibraxion
- Active substance
- inactivated IBR virus
- International non-proprietary name (INN) or common name
- Infectious bovine rhinotracheitis vaccine (inactivated)
- Species
- Cattle
- Anatomical therapeutic chemical veterinary (ATCvet) code
- QI02AA03
Pharmacotherapeutic group
Immunologicals for BovidaeTherapeutic indication
Active immunisation of cattle to reduce the clinical signs of infectious bovine rhinotracheitis (IBR) and field virus excretion.
The onset of immunity is 14 days and the duration of immunity is 6 months.
Authorisation details
- EMA product number
- EMEA/V/C/000051
- Marketing authorisation holder
- Merial
29 Avenue Tony Garnier
69007 Lyon
France - Marketing authorisation issued
- 09/03/2000
- Revision
- 10
Assessment history
Bovalto Ibraxion : EPAR - Procedural steps taken and scientific information after authorisation
English (EN) (222.93 KB - PDF)